125926-17-2

125926-17-2 structure

Name: Sarpogrelate
Chemical Name: 4-[1-(dimethylamino)-3-[2-[2-(3-methoxyphenyl)ethyl]phenoxy]propan-2-yl]oxy-4-oxobutanoic acid
CAS Number: 125926-17-2
Molecular Formula: C₂₄H₃₁NO₆
Molecular Weight: 429.506
Catalog: API Blood system medication Anticoagulant and antiplatelet drugs
Create Date: 2018-05-09 08:00:00
Modify Date: 2024-01-09 13:14:28
Sarpogrelate (MCI-9042) is a new, specific orally active 5-HT2 receptor antagonist, Sarpogrelate (MCI-9042) increases platelet aggregation and has hemostasis effect, and can be used for the research of Buerger’s disease[1].

Name	4-[1-(dimethylamino)-3-[2-[2-(3-methoxyphenyl)ethyl]phenoxy]propan-2-yl]oxy-4-oxobutanoic acid
Synonyms	UNII-19P708E787 Sarpogrelate Hydrochloride Butanedioic acid, mono[2-(dimethylamino)-1-[[2-[2-(3-methoxyphenyl)ethyl]phenoxy]methyl]ethyl] ester 4-{[1-(Dimethylamino)-3-{2-[2-(3-methoxyphenyl)ethyl]phenoxy}-2-propanyl]oxy}-4-oxobutanoic acid Sarpogrelate

Description	Sarpogrelate (MCI-9042) is a new, specific orally active 5-HT2 receptor antagonist, Sarpogrelate (MCI-9042) increases platelet aggregation and has hemostasis effect, and can be used for the research of Buerger’s disease[1].
Related Catalog	Research Areas >> Infection Signaling Pathways >> GPCR/G Protein >> 5-HT Receptor Signaling Pathways >> Neuronal Signaling >> 5-HT Receptor
Target	5-HT2 Receptor
In Vitro	Sarpogrelate (MCI-9042) induces a significant decrease in plasma serotonin (5-HT) concentration and after 2 weeks increases significantly the concentration of whole blood 5-HT. Sarpogrelate (MCI-9042) increases significantly plasma tryptophan concentration after 2 and 4 weeks, and no changes in plasma 5-HIAA concentration. Sarpogrelate (MCI-9042) also has a tendency to increase the concentration of whole blood tryptophan concentration, did not show significant changes in platelet aggregation induced by ADP and collagen. Sarpogrelate (MCI-9042) increases significantly platelet aggregation induced by serotonin after 2 weeks[1].
References	[1]. A Rydzewski, et al. The effect of a 5HT2 receptor antagonist sarpogrelate (MCI-9042) treatment on platelet function in Buerger's disease. Thromb Res. 1996 Dec 15;84(6):445-52.